Mitocin (Mitomycin)

Mitocin is used in oncology to target malignant cells across several tumour types.

• Bladder cancer (intravesical): provides local cytotoxic effect to reduce tumour recurrence.
• Gastric cancer: used as part of combination chemotherapy to improve response rates.
• Pancreatic cancer: contributes to tumour shrinkage when combined with other agents.
• Other solid tumours: incorporated into multi‑drug regimens for various cancers such as breast and lung.

• Mitomycin exerts its antitumour activity by undergoing enzymatic reduction to generate reactive intermediates that form covalent cross‑links between DNA strands. These cross‑links inhibit DNA synthesis and transcription, leading to cell cycle arrest and apoptosis of rapidly dividing cancer cells.

Mitocin may cause a range of adverse reactions that vary in frequency and severity.

Common Side Effects

• Nausea: mild to moderate upset stomach and vomiting.
• Myelosuppression: reduced white blood cells, platelets and red cells.
• Alopecia: hair loss that may be temporary.
• Fatigue: generalized tiredness during treatment.
• Mucositis: inflammation of the mouth and gastrointestinal lining.
• Diarrhoea: loose stools that may require supportive care.

Serious or Rare Side Effects

• Severe bone‑marrow suppression leading to infection or bleeding.
• Renal toxicity: impaired kidney function requiring monitoring.
• Pulmonary fibrosis: scarring of lung tissue causing breathing difficulty.
• Hemorrhagic cystitis: bladder bleeding especially with intravesical use.
• Anaphylactic reactions: rare but potentially life‑threatening allergy.
• Secondary malignancies: risk of new cancers after prolonged exposure.

Mitocin requires careful monitoring and specific safety measures before and during therapy.

• Blood count monitoring: regular CBC to detect myelosuppression early.
• Renal function assessment: evaluate serum creatinine and urine output before each dose.
• Infection risk: avoid use in patients with active severe infections.
• Hepatic impairment: adjust dose or consider alternatives in significant liver disease.
• Concomitant nephrotoxic drugs: use with caution or avoid concurrent use.

Store at 2-8°C: keep refrigerated, protect from light, do not freeze.

Mitocin can interact with other medicines, affecting safety and efficacy.

Major Interactions (Avoid)

• Other myelosuppressive chemotherapy agents: may exacerbate bone‑marrow toxicity.
• High‑dose radiation therapy: increased risk of tissue damage.
• Nephrotoxic antibiotics (e.g., aminoglycosides): heightened renal toxicity.
• Live vaccines: risk of uncontrolled infection due to immunosuppression.

Moderate Interactions (Monitor Closely)

• NSAIDs: may increase risk of renal impairment.
• Anticoagulants: heightened bleeding tendency.
• ACE inhibitors or ARBs: potential additive renal effects.
• Diuretics: monitor electrolytes and fluid balance.
• Erythropoietin‑stimulating agents: adjust dosing based on blood counts.